Analyst Price Target is $8.40
▲ +45.83% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Adaptimmune Therapeutics in the last 3 months. The average price target is $8.40, with a high forecast of $15.00 and a low forecast of $4.00. The average price target represents a 45.83% upside from the last price of $5.76.
Current Consensus is
The current consensus among 5 polled investment analysts is to hold stock in Adaptimmune Therapeutics. This rating has held steady since October 2020, when it changed from a Buy consensus rating.